Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.
The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as age-related macular degeneration (AMD).
AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.
A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.
This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.
Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.
The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.
Dr de Cogan said: “The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.
“Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments.
“The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.
“We believe this is going to be very important in terms of empowering of patients and reducing the cost of treatment to the NHS.”
The Latest on: Age-related macular degeneration
- Global Age-Related Macular Degeneration Market and Competitive Landscape 2020 - ResearchAndMarkets.comon May 12, 2020 at 1:35 am
This research report provides comprehensive insights into the Age-Related Macular Degeneration pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares ...
- STAIRWAY trial shows sustained efficacy of faricimabon May 11, 2020 at 2:37 pm
A with faricimab has the potential to reduce vascular destabilization in age-related macular degeneration, achieving sustained efficacy with a significantly lower frequency of administration as ...
- Network meta-analysis finds little difference among anti-VEGF regimens for wet AMDon May 11, 2020 at 7:38 am
VEGF agents, dosing and injection frequency for the treatment of neovascular age-related macular degeneration found comparable outcomes for all included anti-VEGF regimens, according to a presenter at ...
- Scientists find a new cause of aging-related vision losson May 9, 2020 at 4:02 am
In a new study, researchers have identified an unexpected player in the immune reaction gone awry that causes vision loss in patients with age-related macular degeneration (AMD). The findings suggest ...
- Ocular Therapeutix (OCUL) CEO Antony Mattessich on Q1 2020 Results - Earnings Call Transcripton May 8, 2020 at 12:11 pm
Q1 2020 Results Conference Call May 08, 2020 08:30 AM ET Company Participants Donald Notman - CFO Antony Mattessich - President ...
via Google News and Bing News